Forex, derivatives seen hurting Ranbaxy in Q4 amid atorvastatin woes
This article was originally published in Scrip
Executive Summary
Foreign exchange and derivatives issues are expected to dent Ranbaxy’s performance for the fourth quarter ended December 2012, amid concerns pertaining to the recall of certain lots of its generic atorvastatin in the US.